MegaPro Biomedical announced that in addition to publishing the Phase II results of MPB-1523 MRI contrast medium for hepatocellular carcinoma in the Journal of Magnetic Resonance Imaging (JMRI), a leading radiology journal, the company is also to apply for MPB-1523 orphan drug designation and phase III clinical trials for patients with hepatocellular carcinoma with poor renal function, and has initiated negotiations with major pharmaceutical companies in Taiwan and abroad for authorization.

JMRI is one of the most known medical journals in the world, and the acceptance of the MPB-1523 MRI contrast medium for hepatocellular carcinoma in the Phase II clinical trial for publication is a significant milestone in MegaPro's R&D progress and is expected to have a significant positive impact on the cancer treatment field.

The MPB-1523 nano-iron oxide MRI contrast medium, developed by MegaPro Biomedical using iron oxide nanoparticle (IOP) technology, can be quickly engulfed by immune cells through the modulation of surface hydrophobic properties, and clearly identify malignant tumours without causing heavy metal deposits and nephropathy concerns to patients. MPB-1523 is more useful to patients in the diagnostic and therapeutic process than other contrast mediums currently available.

According to a report by Global Industry Analysts, Inc, the global contrast market will be approximately US$4.9 billion in 2020, with a CAGR of 3.9% from 2021 to 2027, and is estimated to reach US$6.4 billion in 2027.

In MRI, only Gadolinium (Gd) contrast mediums are currently available. Gadolinium is a heavy metal element that has the potential to accumulate in the body over a long period of time. NSF is a disease that causes sclerosis of the skin throughout the body, gradually causing contracture of the joints and even death.

The results of the safety trial showed that there were no serious adverse reactions after the administration of MPB-1523, and that the iron-based MPB-1523 would not cause NSF due to heavy metal residues. In terms of contrast, the results of the trial showed that the contrast between diseased liver cancer cells and normal liver tissue in MRI (T2) images was increased (50%) and the sensitivity of detecting liver cancer cells was significantly enhanced to a high standard of nearly 100%.